Development milestones
We anticipate sterile compounding licensure by the end of Q4 2026 and full commercialization in Q1 2027. These are targets, subject to regulatory approval and operational readiness. Sterile compounding services are not available at this time.
Start with the individual
Personalized medicine considers how a person’s circumstances, needs, and relevant clinical information may inform care. We believe the patient’s experience belongs in that conversation, alongside professional judgment and evidence.
Build around collaboration
Providers, pharmacists, and patients bring different perspectives. Our vision is to support clear communication between them, with roles and responsibilities defined as services are developed.
Connect evidence with practical questions
Scientific progress creates possibilities. We aim to explore those possibilities carefully, asking what is supported by evidence, what is appropriate for the individual, and what can be made useful in practice.
Use technology to strengthen human connection
Technology should help people understand information and communicate clearly. Our guiding principle is to make useful tools serve the relationship between patients and healthcare professionals.
Bring your perspective
Interested in making personalized medicine more practical? Select your primary area of interest so we can follow up.
Connect With Us